Please login to the form below

Not currently logged in
Email:
Password:

European bioinformatics institute appoints GSK's Dr Andrew Leach

He joins the EMBL-EBI as head of chemistry services

EMBL EBI Dr Andrew LeachThe European Bioinformatics Institute (EBI) has appointed Dr Andrew Leach as head of chemistry services, who will take up the position on 1 September.

Dr Leach moves to the institute - a part of the European Molecular Biology Laboratory (EMBL) - from GSK Research and Development, which he joined in 1994 as a research scientist and manager.

From there, Dr Leach progressed to director of computational chemistry, Europe before taking on his most recent role as head of biomolecular sciences in which he delivered biophysics, structural biology and bioanalytical data analysis and expertise.

Between 2006 and 2015, he served as a trustee of the Cambridge Crystallographic Data Centre and was editor of the Journal of Computer-Aided Molecular Design from 1997 to 2012.

Dr Rolf Apweiler, director of EMBL-EBI, said: “Dr Leach is greatly respected in the pharma world and brings with him a wealth of knowledge and experience in drug discovery and cheminformatics.

“As a user of EMBL-EBI resources throughout his career, Andrew brings unique insights into the pharma industry's user requirements and an exciting vision for future exploitation of opportunities in data, analytics and computation.”

Dr Leach said: “I am honoured to have been chosen to take on the leadership of EMBL-EBI's highly successful chemistry services.

“I know first-hand the huge value that EMBL-EBI's resources bring to bench scientists in the industry and am looking forward to taking EMBL-EBI's chemical biology data services to the next level.”

29th March 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you in the world of the patient...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics